{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:26:21Z","timestamp":1727324781726},"reference-count":30,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Objective: This study investigated the association between patient treatment capacity rates and the percentage of racial\/ethnic minorities at the county level. \r\nDesign: Ecological study at the county level.\r\nExposure: The percentages of racial\/ethnic minorities and the people living in poverty in 3,140 counties serve as the main exposure and confounder variables.\r\nMain outcome measure: \u201cNo or low patient capacity\u201d was defined as a patient capacity rate less than or equal to the 40th percentile of the distribution. Patient capacity rates were calculated by adding the maximum number of patients X-waivered providers could potentially treat in each county.\r\nResult: Counties in higher racial\/ethnic minority quintiles had significantly lower odds of \u201cno or low patient capacity\u201d than those in the lowest quintile in multiple logistic regression (adjusted odds ratio, 0.29; 95 percent CI, 0.14-0.61).\r\nConclusion: Since racial\/ethnic minorities continue to have limited access to buprenorphine, as shown in individual-level studies, merely increasing treatment capacity is largely insufficient.<\/jats:p>","DOI":"10.5055\/jom.0858","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:36:00Z","timestamp":1727289360000},"page":"275-279","source":"Crossref","is-referenced-by-count":0,"title":["Association between buprenorphine capacity rates and percentages of ethnic\/racial minorities at the county level in the United States"],"prefix":"10.5055","volume":"20","author":[{"given":"Saharnaz","family":"Nedjat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3008","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"91305","unstructured":"Centers for Disease Control and Prevention: Understanding the opioid overdose epidemic. 2022. Available at https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html. Accessed June 14, 2023."},{"key":"91306","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, et al.: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; 8(3): CD002209.","DOI":"10.1002\/14651858.CD002209.pub2"},{"key":"91307","unstructured":"US Department of Health and Human Services: Facing addiction in America: The surgeon general's report on alcohol, drugs, and health. Washington, DC: US Office of the Surgeon General, 2016. Available at https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/surgeon-generals-report.pdf. Accessed June 17, 2023."},{"key":"91308","doi-asserted-by":"crossref","unstructured":"Cicero TJ, Inciardi JA: Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med. 2005; 353(17): 1863-1865.","DOI":"10.1056\/NEJM200510273531724"},{"key":"91309","unstructured":"US Department of Health and Human Services: Rates of patient capacity and OUD treatment need in the United States by count. 2018. Available at https:\/\/oig.hhs.gov\/oei\/maps\/waivered-providers\/index.html. Accessed July 3, 2023."},{"key":"91310","unstructured":"Grimm CA: Geographic disparities affect access to buprenorphine services for opioid use disorder. US Department of Health and Human Services. Office of Inspector General. 2020. Available at https:\/\/oig.hhs.gov\/oei\/reports\/oei-12-17-00240.pdf. Accessed July 17, 2023."},{"key":"91311","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA): Removal of DATA waiver (X-waiver) requirement MAT ACT. 2023. Available at https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement. Accessed February 13, 2024."},{"key":"91312","doi-asserted-by":"crossref","unstructured":"Hollander MAG, Chang CH, Douaihy AB, et al.: Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use. Drug Alcohol Depend. 2021; 227: 108927.","DOI":"10.1016\/j.drugalcdep.2021.108927"},{"key":"91313","doi-asserted-by":"crossref","unstructured":"Hadland SE, Wharam JF, Schuster MA, et al.: Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017; 171(8): 747-755.","DOI":"10.1001\/jamapediatrics.2017.0745"},{"key":"91314","doi-asserted-by":"crossref","unstructured":"Nguyen T, Ziedan E, Simon K, et al.: Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic. JAMA Netw Open. 2022; 5(6): e2214765.","DOI":"10.1001\/jamanetworkopen.2022.14765"},{"key":"91315","doi-asserted-by":"crossref","unstructured":"Schuler MS, Dick AW, Stein BD: Growing racial\/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. Drug Alcohol Depend. 2021; 223: 108710.","DOI":"10.1016\/j.drugalcdep.2021.108710"},{"key":"91316","doi-asserted-by":"crossref","unstructured":"Goedel WC, Shapiro A, Cerda M, et al.: Association of racial\/ ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020; 3(4): e203711.","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"91317","doi-asserted-by":"crossref","unstructured":"Jackson DS, Tiako MJN, Jordan A: Disparities in addiction treatment: Learning from the past to forge an equitable future. Med Clin. 2022; 106(1): 29-41.","DOI":"10.1016\/j.mcna.2021.08.008"},{"key":"91318","doi-asserted-by":"crossref","unstructured":"Guerrero EG, Amaro H, Khachikian T, et al.: A bifurcated opioid treatment system and widening insidious disparities. Addict Behav. 2022; 130: 107296.","DOI":"10.1016\/j.addbeh.2022.107296"},{"key":"91319","doi-asserted-by":"crossref","unstructured":"Hansen H, Roberts SK: Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. In Netherland J (ed.): Critical Perspectives on Addiction. Leeds: Emerald Group Publishing Limited, 2012: 79-102.","DOI":"10.1108\/S1057-6290(2012)0000014008"},{"key":"91320","doi-asserted-by":"crossref","unstructured":"Knudsen HK, Studts JL: Physicians as mediators of health policy: Acceptance of Medicaid in the context of buprenorphine treatment. J Behav Health Serv Res. 2019; 46(1): 151-163.","DOI":"10.1007\/s11414-018-9629-4"},{"key":"91321","doi-asserted-by":"crossref","unstructured":"Drake C, Donohue JM, Nagy D, et al.: Geographic access to buprenorphine prescribers for patients who use public transit. J Subst Abuse Treat. 2020; 117: 108093.","DOI":"10.1016\/j.jsat.2020.108093"},{"key":"91322","doi-asserted-by":"crossref","unstructured":"Langabeer JR, Stotts AL, Cortez A, et al.: Geographic proximity to buprenorphine treatment providers in the US. Drug Alcohol Depend. 2020; 213: 108131.","DOI":"10.1016\/j.drugalcdep.2020.108131"},{"key":"91323","unstructured":"United States Census Bureau: County population by characteristics: 2020-2021. 2020. Available at https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2020s-counties-detail.html. Accessed May 3, 2023."},{"key":"91324","unstructured":"US Department of Commerce, Bureau of the Census: Small Area Income and Poverty Estimates (SAIPE) Program. 2020. Available at https:\/\/view.officeapps.live.com\/op\/view.aspx?src=https%3A%2F%2Fwww.ers.usda.gov%2Fwebdocs%2FDataFiles%2F48747%2FPovertyEstimates.xlsx%3Fv%3D3767.3&wdOrigin=BROWSELINK. Accessed May 2, 2023."},{"key":"91325","unstructured":"Department of Health and Human Services: Medication assisted treatment for opioid use disorders; final rule. ed. 81 Fed. Reg. 44712. 2016. Available at https:\/\/www.federalregister.gov\/documents\/2016\/09\/27\/2016-23277\/medication-assistedtreatment-for-opioid-use-disorders-reporting-requirements. Accessed May 13, 2023."},{"key":"91326","doi-asserted-by":"crossref","unstructured":"Duncan A, Anderman J, Deseran T, et al.: Monthly patient volumes of buprenorphine-waivered clinicians in the US. JAMA Netw Open. 2020; 3(8): e2014045.","DOI":"10.1001\/jamanetworkopen.2020.14045"},{"key":"91327","doi-asserted-by":"crossref","unstructured":"Stein BD, Sorbero M, Dick AW, et al.: Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016; 316(11): 1211-1212.","DOI":"10.1001\/jama.2016.10542"},{"key":"91328","doi-asserted-by":"crossref","unstructured":"Jones CM, McCance-Katz EF: Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction. 2019; 114(3): 471-482.","DOI":"10.1111\/add.14436"},{"key":"91329","doi-asserted-by":"crossref","unstructured":"Saloner B, Lin L, Simon K: Geographic location of buprenorphine- waivered physicians and integration with health systems. J Subst Abuse Treat. 2020; 115: 108034.","DOI":"10.1016\/j.jsat.2020.108034"},{"key":"91330","doi-asserted-by":"crossref","unstructured":"Egan JE, Casadonte P, Gartenmann T, et al.: The physician clinical support system-buprenorphine (PCSS-B): A novel project to expand\/improve buprenorphine treatment. J Gen Intern Med. 2010; 25(9): 936-941.","DOI":"10.1007\/s11606-010-1377-y"},{"key":"91331","doi-asserted-by":"crossref","unstructured":"Robbins JL, Bonuck K, Thuillier P, et al.: Differences in perceived clinical knowledge uptake among health profession students and licensed clinicians receiving buprenorphine waiver training in Oregon. Subst Abus. 2022; 43(1): 825-833.","DOI":"10.1080\/08897077.2021.2010260"},{"key":"91332","doi-asserted-by":"crossref","unstructured":"Andrews CM, Grogan CM, Westlake MA, et al.: Do benefits restrictions limit Medicaid acceptance in addiction treatment? Results from a national study. J Subst Abuse Treat. 2018; 87: 50-55.","DOI":"10.1016\/j.jsat.2018.01.010"},{"key":"91333","doi-asserted-by":"crossref","unstructured":"Qato DM, Watanabe JH, Clark KJ: Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US. JAMA Health Forum. 2022; 3(8): e222839-e222839.","DOI":"10.1001\/jamahealthforum.2022.2839"},{"key":"91334","unstructured":"Hartge P, Cahill J: Ecologic studies. Section IV. Special topics. In Rothman KJ, Greenland S, Lash T (eds.): Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2008."}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3679\/3966","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3679\/3966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:36:34Z","timestamp":1727289394000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0858","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}